Literature DB >> 24154847

[Informations and recommendations of the German Respiratory Society and the Paul-Ehrlich-Society for chemotherapy concerning the outbreak of influenza A(H7N9) virus infections in humans].

G Höffken1, P Kern, U Buchholz, S Ewig, T Schaberg.   

Abstract

In March 2013, the first cases of avian influenza virus infections in humans were reported by the authorities of the PR of China to the World Health Organization. This influenza A(H7N9) virus comprises genes of at least four different avian influenza viruses, some segments mimicking human-like influenza-signatures. Until 11 August, 2013 135 humans were infected, 44 (33%) died. The clinical course is characterized by fever, cough, gastrointestinal symptoms, lympho- and thrombopenia as well by the rapid onset of an acute respiratory distress syndrome in nearly 25% of the cases. Although human to human transmission may have occurred only in the context of three clusters, strict hygiene measures should be instituted and any suspect case should be reported to the local health authorities immediately. The detection of influenza A(H7N9) is based on real-time polymerase chain reaction (PCR). Antiviral treatment should be initiated as early as possible for suspect, probable or confirmed cases, even when 48 hours have passed after symptom onset. At present the future development of this epidemic cannot be predicted. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24154847     DOI: 10.1055/s-0033-1344807

Source DB:  PubMed          Journal:  Pneumologie        ISSN: 0934-8387


  2 in total

1.  [Rare infections of the lungs not endemic in Germany].

Authors:  Frieder Pfäfflin; Miriam Songa Stegemann
Journal:  Pneumologe (Berl)       Date:  2020-11-03

2.  Infection control strategies for patients and accompanying persons during the COVID-19 pandemic in German hospitals: a cross-sectional study in March-April 2021.

Authors:  A Bludau; S Heinemann; A A Mardiko; H E J Kaba; A Leha; N von Maltzahn; N T Mutters; R Leistner; F Mattner; S Scheithauer
Journal:  J Hosp Infect       Date:  2022-04-09       Impact factor: 8.944

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.